Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications

File for Quick & Easy Patent Protection with PowerPatent.

The Seventh Sense Biosystems, Inc. patent solves the following problem:

A variety of techniques and methods available for sensing and responding to situations that a subject was exposed, including the sensing of physiological condition in a mammal and / or a surrounding environment. The other technique is to save and / or withdrawing a fluid from a mammal, such as blood. While many of these techniques are suitable for various purposes, techniques that one or more features like more simplicity and flexibility in the use of beneficial.

Our analysis of this patent is as follows:

Seventh Sense Biosystems, Inc.’s patent US 9113836 B2 deals with Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications.
The present invention generally relates to devices and techniques associated with diagnostics, therapy, and other applications, including the skin-associated applications, for example, devices for delivering and / or withdrawing fluid from the members, for example, through the skin. In some embodiments, the device includes a system for access to an extractable medium from and / or through the skin of the subject to an access site, and a pressure regulator supported by a support structure , able to create a pressure differential across the skin at least a portion of the site access. The device may also include, in some cases, a sensor supported by the support structure for determining at least one state of the extractable medium from the head, and optionally a signal generator supported structure support for the creation of a signal related to the condition of the medium determined by the sensor.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, , Research Foundation For Mental Hygiene, Inc., , The Progeria Research Foundation, Inc. patent solves the following problem:

The prospect of reversing senescence and restoring the proliferative potential of cells has implications in many fields of endeavor. Many diseases of aging associated with the loss of its potential. Furthermore, the terrible disease, Progeria, which is often described in the literature as a premature aging syndrome based on appearance, associated with the loss of proliferative potential of these cells. Werner Syndrome and Hutchinson-Gilford Progeria Syndrome (HGPS) is two progeroid disease. A large clinical difference between the two is that the start of Hutchinson-Gilford Progeria Syndrome (sometimes called progeria of childhood) occur within the first decade of life, while the first evidence of Werner Syndrome (sometimes called progeria to maturity) so only after puberty, with all the symptoms can be found in individuals 20 to 30 years old.

Our analysis of this patent is as follows:

The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, , Research Foundation For Mental Hygiene, Inc., , The Progeria Research Foundation, Inc.’s patent US 9115400 B2 deals with LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis.
Said there was a point mutation in the LMNA gene cause HGPS. These mutations activate a cryptic splice site in the LMNA gene, which leads to the deletion of exon 11 and the generation of a normal Lamin A protein product that is 50 amino acid shorter than normal protein. In addition to the novel Lamin A different protein and nucleic acid encoding these different ways to use these molecules to understand biological conditions associated with a LMNA mutation in a subject (eg, HGPS, arteriosclerosis, and other diseases of age related), methods of treating such conditions, the selection of treatment, methods of screening for compounds that influence Lamin a activity, and methods of influence the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in the example of the described methods also given, as protein-specific cost agents, such as antibodies, that bind specifically to at least one epitope one Lamin another protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provides kits for performing the methods described herein.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Sequences, antibodies, methods and kits for detection and in vitro assay of periostin, in order to provide a diagnosis, follow-up or prognosis of diseases and biological phenomena involving periostin

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Synarc Sas, , Inserm patent solves the following problem:

Our analysis of this patent is as follows:

Synarc Sas, , Inserm’s patent US 9115190 B2 deals with Sequences, antibodies, methods and kits for detection and in vitro assay of periostin, in order to provide a diagnosis, follow-up or prognosis of diseases and biological phenomena involving periostin.
Detection of periostin from 6 to 30 amino acids and which includes all or part of the peptide sequences SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, or a homologous peptide. Antibody suitable for specific recognition minimally one of these file detection, including an anti-periostin antibody, is disclosed. Periostin detection and dosage processes and kits that use these antibodies were also expressed. A periostin marker for early diagnosis, tracking and recovery of pathologies including periostin, including benign osteolysis as inflammatory diseases, including diseases osteoarticular, and severe osteolysis, bone cancer metastases, given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-EphrinB2 antibodies and methods using same

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Genentech, Inc. patent solves the following problem:

Development of a vascular supply is a fundamental requirement for many physiological and pathological processes. Actively growing tissues such as embryos and tumors require adequate blood supply. They satisfy this need by bringing in pro-angiogenic factors, which promote new blood vessel formation by a process called angiogenesis. Vascular tube formation is a complex but orderly biological event involving all or many of the following steps: a) endothelial cells (ECs) proliferate from the current evacuation center or the difference from the ancestor cells; b) ECs migrate and coalesce to form cord-like structures; c) vascular cords then pass tubulogenesis to form vessels with a central lumen; d) existing cords or vessels send sprouts to form secondary vessels; e) primitive vascular plexus undergo further remodeling and reshaping; and f) peri-endothelial cells are recruited within the endothelial tubes, providing maintenance and modulatory functions to the vessels; such cells including pericytes for small capillaries, smooth muscle cells for larger vessels, and myocardial cells in the heart. Hanahan, Science 277: 48-50 (1997); Hogan & Kolodziej, Nat. Pin genet. 3: 513-23 (2002); Lubarsky & Krasnow, Cell 112: 19-28 (2003).

Our analysis of this patent is as follows:

Genentech, Inc.’s patent US 9115191 B2 deals with Anti-EphrinB2 antibodies and methods using same.
invention provides anti-EphrinB2 antibody, and compositions containing and methods of using these antibodies.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods and compositions for genetic and retinal disease

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Retinol Solutions Llc patent solves the following problem:

Proper vascular pattern of the retina is essential for ocular development and visual acuity. Abnormal vessel growth during development or maturity some pretty common diseases such as retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Normal retinal development occurs by building vessels in the optic nerve head and spreading over the retina to form a dense network. Connolly, HS, et al, Microvasc Res, 1988; 36: 275-290; Provis, JM, program Retin Eye Res, 2001; 20: 799-821; FRUTTIGER, M, Invest Ophthalmol Vis Sci, 2002; 43: 522-527. Development proceeds through the formation of the first vessels along the surface of the developing retina from different vessels begin to give into the capillary beds that form the outer and inner plexiform layers of the retina. Connelly, 1988; Provis, 2001, FRUTTIGER, 2002. Vascular growth mediated by a series of growth factors that direct the formation and extension of new vessels. Retinal development is unique in the concentration and type of signaling teachers used to promote angiogenic sprouting from the vascular network and the construction of the last capillary architecture. Ohlmann, A, et al, J Neurosci, 2005; 25: 1701-1710. Something hypothesized to be involved in the formation of the first retinal vasculature and retinal capillaries is the protein Norrin. Norrin, is a 131 amino acid long protein secreted into the extracellular space. Meitinger, T, et al, Nat genet, 1993; 5: 376-380; Berger, K, et al, Hum mol genet, 1996; 5: 51-59. Two leading heritage identifies general framework Norrin protein: a signal peptide directs localization of molecules; and a cysteine-knot design gives the tertiary confirmation required for receptor binding and activation of signal transduction.

Our analysis of this patent is as follows:

Retinol Solutions Llc’s patent US 9114078 B2 deals with Methods and compositions for genetic and retinal disease.
A creative approach for the treatment or prevention of vascular diseases of the retina given. A Norrin compound optionally administered to a subject directly and / or as expressed by a cell. The presence of the compound is either protective or therapeutic for a pathological condition of the retina. Preferred pathological conditions are associated with loss or mutation in the Norrin protein and preferably with Norrie disease, févr, or macular degeneration.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

File for Quick & Easy Patent Protection with PowerPatent.

The Labrys Biologics, Inc. patent solves the following problem:

CGRP (calcitonin gene-related peptide) is a 37 amino acid neuropeptide, which belonged to a family of peptides including calcitonin, adrenomedullin and Amylin. In men, the two forms of CGRP (-CGRP and -CGRP) and there are similar activities. They vary from three amino acids and show differential distribution. At least two CGRP receptor subtypes also account for the differential activity. CGRP is a neurotransmitter in the central nervous system, and that showed a potent vasodilator in the periphery, where CGRP-containing neurons closely associated with blood vessels. CGRP-mediated vasodilatation associated with neurogenic inflammation, as part of a cascade of events that results in extravasation of plasma and vasodilation in the microvasculature and now migraine.

Our analysis of this patent is as follows:

Labrys Biologics, Inc.’s patent US 9115194 B2 deals with Antagonist antibodies directed against calcitonin gene-related peptide and methods using same.
invention showing the means for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headache (eg, migraine, cluster headaches, and tension headaches) and the warm gush, by administering an anti-CGRP antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Therapeutic DLL4 binding proteins

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Abbvie Inc. patent solves the following problem:

Cell-to-cell communication is essential for many biological processes like the difference, multiply, and homeostasis. A system used in a wide range of eukaryotes are notch-marked path. This way, especially in the notch receptor, is critical for functional tumor angiogenesis. Thus, inhibition of notch receptor function, blockage notch receptor, and / or blockage of the notch-marked paths are potential ways for anti-cancer therapy and composition. The small molecule inhibitor of notch receptor that proved toxic because they suppress wild type (normal) tissue expressing notch receptor throughout the body. Thus, the different members of the notch-marked path should be considered as potential targets for therapeutics.

Our analysis of this patent is as follows:

Abbvie Inc.’s patent US 9115195 B2 deals with Therapeutic DLL4 binding proteins.
DLL4 binding protein described here, including the antibody, CDR-grafted antibody, humanized antibody, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and / or VEGF activity. DLL4 binding proteins are useful for the treatment or prevention of cancer and tumors, and especially for the treatment or prevention of tumor angiogenesis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

VMP-like sequences of pathogenic Borrelia species and strains

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Board Of Regents, The University Of Texas System patent solves the following problem:

A. Field of Invention

Our analysis of this patent is as follows:

Board Of Regents, The University Of Texas System’s patent US 9115193 B2 deals with VMP-like sequences of pathogenic Borrelia species and strains.
The present invention relates to sequences of DNA encoding VMP-like polypeptides of pathogenic Borrelia, the use of artificial DNA vector expressing the polypeptides, the encoded amino acid sequence, using DNA and amino acid sequences in the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed is the use of nucleic acid consequences such investigation or primers for the detection of the organism causing Lyme disease, relapsing fever, or pain, and the kit is designed to perform the methods of using described polypeptides , of DNA and antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of treatment using ex vivo expansion of cord blood T cells

File for Quick & Easy Patent Protection with PowerPatent.

The Duke University patent solves the following problem:

The development of techniques for spreading T cell population in vitro very important to many of the recent advances in the understanding of T cell recognition of antigen and T cell activation. The development of culture methods for the generation of human antigen-specific T cell clones useful in defining antigens expressed by pathogens and disease recognized by T cells to establish methods of immunotherapy in treating a variety of diseases man. Antigen-specific T cells can be expanded in vitro for use in adoptive cellular immunotherapy infusions of such T cells were shown to have anti-tumor reactivity in a tumor-bearing hosts. Adoptive immunotherapy is also used to treat infections in immunocompromised individuals.

Our analysis of this patent is as follows:

Duke University’s patent US 9114100 B2 deals with Methods of treatment using ex vivo expansion of cord blood T cells.
If the way to improve ex vivo proliferation of T cell population, the method comprising contacting the T cell populations to IL-7 and anti-CD3 / CD28 antibody activation and expansion of T cell populations. Also given is the way to produce an antigen-specific cytotoxic T cell population comprising actuating a CD3 / CD28-expanded T cell populations against an antigen (eg, a cancer cell) in before at least one of IL-7, IL-12, and IL-15, or a combination thereof. Also given is the way to treat T cell lymphopenia in a subject, comprising administering to a CD3 / CD28-expanded T cell population in the subject.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Selective oxidation of 5-methylcytosine by TET-family proteins

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Children’s Medical Center Corporation patent solves the following problem:

DNA methylation and demethylation play important roles in various aspects of mammal development, as well as the body cells during the diff and the aged. Important, these processes are known to be very aberrant during tumorigenesis and cancer (A. Bird, Genes Dev 16: 6-21 (2002); W. Reik, Nature 447: 425-432 (2007); K. Hochedlinger, Nature 441: 1061-1067 (2006); MA Surani Cell 128: 747-762 (2007); JB Gurdon, Annu Rev Cell Dev Biol 22: 1-22 (2006)).

Our analysis of this patent is as follows:

Children’s Medical Center Corporation’s patent US 9115386 B2 deals with Selective oxidation of 5-methylcytosine by TET-family proteins.
The present invention provides for novel methods for the preparation and knowledge of cytosine methylation status of the DNA. The invention is based on the recognition of a novel and surprising catalytic activity for families tet protein, which is TET1, TET2, TET3, and CXXC4. The novel activity related to the enzyme that can or cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.